Blake Mielke

 

 

 

 

 

 

 

 

 

 

 

 

 

Mr. Mielke is a fundamental research analyst at Causeway. He joined the firm in September 2023. His current responsibilities include coverage of companies in the technology and communication services sectors.

Prior to joining Causeway, Mr. Mielke was a senior equity research associate at Jefferies, covering communications infrastructure. From 2020 to 2021, he was an equity research associate at Stifel, covering application and security software.

Bennett Bullock

 

 

 

 

 

 

 

 

 

 

 

 

Mr. Bullock is a senior natural language processing/artificial intelligence analyst at Causeway. He joined the firm in December 2022.

Prior to joining Causeway, Mr. Bullock worked at several startups that focused on leveraging NLP in personal finance, health, and customer service. Highlights of his career include building the Bloomberg Social Velocity terminal function at Bloomberg, publishing a Portuguese-language book on AI, writing a programming language, and demoing his software to Canadian Prime Minister Trudeau in the Creative Destruction Labs event in Toronto, Canada.

Nicholas Wells, CFA

 

 

 

 

 

 

 

 

 

 

 

 

 

Mr. Wells is a fundamental senior research analyst at Causeway. He joined the firm in May 2023. His current responsibilities include coverage of companies in the consumer discretionary and consumer staples sectors.

Prior to joining Causeway, Mr. Wells was a partner at Poplar Forest Capital, covering the consumer discretionary, consumer staples, and materials sectors. From 2013 to 2017, he was a research associate at Capital Group Companies. Prior to that, Mr. Wells was a research associate at UBS Investment Bank.

Marshall Dong

 

 

 

 

 

 

 

 

 

 

 

 

 

Mr. Dong is a quantitative research analyst at Causeway. He joined the firm in March 2023. His current responsibilities include alpha research and alternative data analysis.

From 2020 to 2023, Mr. Dong was at data scientist at Point72 Asset Management, covering US industrials sector. Prior to that, he was a senior strategy/analytics consultant at Deloitte LLP.

Kathryn Hall

Kathryn Hall is a business development associate. She joined the firm in April 2022.

From 2021 to 2022, Ms. Hall worked in sales and marketing at Wisetail, an Intertek Company.

Danielle Durkovic

Danielle Durkovic is a reporting analyst. She joined the firm in November 2022.

Ryan Greenwald, CPA

Mr. Greenwald is a fundamental research analyst at Causeway. He joined the firm in November 2022 with current coverage responsibilities including global utilities & clean energy.

Prior to joining Causeway, Mr. Greenwald spent over five years as a sell side equity analyst supporting #1 Institutional Investor ranked teams at Bank of America and Wolfe Research, covering US utilities & clean energy along with airfreight & surface transportation.

Kate Byrne-Slepicka

Ms. Byrne-Slepicka is a fundamental research analyst at Causeway. She joined the firm in November 2022. Her current responsibilities include coverage of companies in the financials and materials sectors.

Prior to joining Causeway, Ms. Byrne-Slepicka was a senior investment risk analyst at Global Atlantic Financial Group. Prior to 2021, Ms. Byrne-Slepicka was an investment portfolio analyst at Global Atlantic.

Michael Gianatasio

Mr. Gianatasio is a fundamental research analyst at Causeway. He joined the firm in October 2022. His current responsibilities include coverage of companies in the industrials, materials, and energy sectors.

Prior to joining Causeway, Mr. Gianatasio was an investment banking analyst at Barclays in their global industrials group.

Gavin Scott

Mr. Scott is a fundamental senior research analyst at Causeway. He joined the firm in August 2022. His current responsibilities include coverage of companies in the pharmaceuticals and biotechnology sectors.

Prior to joining Causeway, Mr. Scott was vice president of Equity Research Large Cap Biotech at J.P. Morgan. From 2017 to 2019, he was an associate at Goldman Sachs covering large cap biopharma. Prior to that, Mr. Scott was an associate at Jefferies LLC, covering Global Large Cap Pharma.